Welcome To Iconocast

How to add a URL link from your web site to the Iconocast web sites

Virtual tour of Southern California

Recent News and Articles on the Keywords: macugen + anaphylaxis + rare  Related to the article below (Last Update: 12/1/2008)

News results: Standard Version | Text Version | Image Version

Browse Top Stories Recent Last hour Last day Past week Past month Archives All dates Blogs News Alerts RSS | Atom About Feeds Your search - macugen + anaphylaxis + rare - did not match any documents. Suggestions: Make sure all words are spelled correctly. Try different keywords. Try more general keywords. Try fewer keywords. Try Google Blog Search. Also, you can browse today's headlines on the Google News homepage.

Recent News and Articles on the Keywords: macugen + [doc] + 0.23  Related to the article below (Last Update: 8/7/2008)

New treatments for macular degeneration Casa Grande Valley Newspapers, AZ - Jul 16, 2008 The first anti-VEGF drug approved by the FDA for the treatment of macular degeneration was Macugen (pegaptanib). Blocking the activity of one type of VEGF, ... SEC Form 8-K Current Report.pdf Sydney Morning Herald, Australia - Jul 8, 2008 Examples include Macugen. (pegaptanib sodium) and Lucentis. (ranibizumab, formerly RhuFab V2), both of which may be injected into the eye as frequently as ... Patients challenge ban on sight-saving NHS treatment Telegraph.co.uk, United Kingdom - Jul 10, 2008 Lucentis, the most effective, can cost up to ?28000 for a course of 14 monthly injections, while the other option, Macugen, costs ?4000 a year. ... OSI Pharmaceuticals Inc. Q2 2008 Earnings Call Transcript Seeking Alpha, NY - Jul 23, 2008 We signed a definitive agreement with a new company, led largely by the Eyetech sales leadership, to transfer the Macugen business in a deal focused on ...OSIP Gilead Sciences: Industry Landscape, Strong Growth Make It a Buy Seeking Alpha, NY - Jul 20, 2008 Macugen?, marketed by OSI Pharmaceuticals, Inc. under a royalty-paying collaborative agreement with GILD, for the treatment of neovascular age-related ...GILD Mesoblast Limited (ASX:MSB) Announce Pre-clinical Trials Show ... ABN Newswire (press release), Australia - Jul 10, 2008 Two of these agents, marketed under the names Lucentis and Macugen, have been approved by global regulatory bodies and distributed by Genentech, Novartis, ...ASX:MSB Pfizer Reports Second-Quarter 2008 Results FOXBusiness - Jul 23, 2008 ... ALL OTHER 619 1025 (40) 181 665 (73) 438 360 22 ZYRTEC / ZYRTEC D 8 385 (98) 8 385 (98) - - - - ALLIANCE REVENUE (Aricept, Exforge, Macugen, Mirapex, ...PFE Test-Aankoop.be Test-Aankoop lanceert nieuw geneesmiddel! Test-Aankoop.be, Belgium - Jul 31, 2008 De communicatie rond Macugen is daar een sterk voorbeeld van. Macugen is een voorschriftplichtig geneesmiddel tegen maculadegeneratie. ... Geneesmiddel tegen motivatiegebrek Het Nieuwsblad, Belgium - Jul 31, 2008 Test-Aankoop verwijst naar de website van het geneesmiddel Macugen van gigant Pfizer over de oogaandoening maculadegeneratie; die site werd in april dit ... 聚乙二醇化蛋白质类药物或将改变现有生物工程药物市场面貌 中国生物技术信息网, China - Aug 4, 2008 2005年，FDA又批准由辉瑞公司研制的治疗老年黄斑变性的新PEG制剂Macugen（其主要成分为能抑制血管内皮生长因子的蛋白质类药物Pegaptanib）；2006年，批准了由安进公司 ...

Macugen: rare cases of anaphylaxis/anaphylactoid reactions

Rare cases of anaphylaxis/anaphylactoid reactions, including angioedema, have been reported in the post-marketing experience following the Macugen ( Pegaptanib sodium injection ) intravitreal administration procedure

Macugen is indicated for the treatment of neovascular ( wet ) age-related macular degeneration, and is administered once every six weeks by intravitreous injection.

Since market introduction in the United States, there have been rare reports of anaphylaxis/ anaphylactoid reactions, including angioedema, following administration of Macugen along with various medications administered as part of the injection preparation procedure.

A direct relationship to Pegaptanib or any of the various medications administered as part of the injection preparation procedure or other factors has not been established in these cases.

The patient’s medical history for hypersensitivity reactions should be evaluated prior to performing the intravitreal injection procedure.

Macugen is contraindicated in patients with ocular or periocular infections.
Macugen is contraindicated in patients with known hypersensitivity to Pegaptanib sodium or any other excipient in this product.

Source: FDA, 2006